Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells

Detalles Bibliográficos
Autor principal: Dhanasiri, Sujith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198474/
https://www.ncbi.nlm.nih.gov/pubmed/31754250
http://dx.doi.org/10.1038/s41409-019-0749-0
_version_ 1783528992213565440
author Dhanasiri, Sujith
author_facet Dhanasiri, Sujith
author_sort Dhanasiri, Sujith
collection PubMed
description
format Online
Article
Text
id pubmed-7198474
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71984742020-05-06 Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells Dhanasiri, Sujith Bone Marrow Transplant Correspondence Nature Publishing Group UK 2019-11-21 2020 /pmc/articles/PMC7198474/ /pubmed/31754250 http://dx.doi.org/10.1038/s41409-019-0749-0 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Correspondence
Dhanasiri, Sujith
Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
title Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
title_full Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
title_fullStr Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
title_full_unstemmed Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
title_short Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
title_sort response to: olry de labry lima a et al., cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198474/
https://www.ncbi.nlm.nih.gov/pubmed/31754250
http://dx.doi.org/10.1038/s41409-019-0749-0
work_keys_str_mv AT dhanasirisujith responsetoolrydelabrylimaaetalcosteffectivenessoflenalidomidemaintenanceinpatientswithmultiplemyelomawhohaveundergoneautologoustransplanthematopoieticprogenitorcells

Ejemplares similares